Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + tremelimumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Trastuzumab is a monoclonal antibody targeting HER2 (human epidermal growth factor receptor 2), used in the treatment of HER2-positive breast cancer. Tremelimumab is a monoclonal antibody targeting CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), acting as an immune checkpoint inhibitor to enhance T-cell activation and antitumor immune responses. The combination of trastuzumab and tremelimumab has been explored in clinical trials for advanced or metastatic HER2-positive breast cancer, including cases with brain metastases or resistance to prior trastuzumab-based therapies[1][2]. This combination aims to leverage both targeted therapy against HER2 and immune checkpoint blockade to improve outcomes in difficult-to-treat populations.
- Other names
- trastuzumab plus tremelimumabtremelimumab plus trastuzumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab + tremelimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + tremelimumab.